A new rapid turnaround genetic test for spinal muscular atrophy, found to reduce time to results from 21 days to 4 days, will be offered at no charge to qualified individuals in the United States as part of the SMA Identified program.
Synologic, Inc announced that following disappointing top-line data from a phase 1b/2a study, the Company will discontinue the development of SYNB1020 for the treatment of hyperammonemia.
Evidence-based therapies are available for the acute symptomatic treatment of migraine in children and adolescents, but evidence is lacking for the impact of many treatments for migraine prevention.
The injection of onabotulinumtoxinA toward the sphenopalatine ganglion in patients with trigeminal neuralgia may not reduce the number of attacks.
Wakix is a selective H3 receptor antagonist/inverse agonist and the first treatment for narcolepsy that is not scheduled as a controlled substance.
The risk factors for tardive dyskinesia in patients taking antipsychotics include age, comorbid diagnoses, and high medication dosages.
Veterans diagnosed with a traumatic brain injury (TBI) are at a higher risk for suicide in comparison with those without a TBI diagnosis, especially when the severity is moderate to severe.
Remote electrical neuromodulation may represent a safe and effective option for the acute treatment of migraine.
The FDA has rejected the supplemental New Drug Application for Hetlioz (tasimelteon; Vanda Pharmaceuticals) for the treatment of jet lag disorder.
Canadian researchers found data that showed social determinants of health are linked to migraine prevalence across sexes.